Business Context and Reporting Period
This Form 8-K Current Report was filed by Pliant Therapeutics, Inc. on December 8, 2025, covering events occurring on December 2, 2025. The filing addresses a significant change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Executive Departure: On December 2, 2025, the Company notified Éric Lefebvre, M.D., Chief Medical Officer (CMO), that his employment will terminate effective December 15, 2025.
- Transition Plan: Dr. Lefebvre is expected to continue assisting the Company as a consultant post-separation to support the transition of his responsibilities.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, market outlook, or specific risk factors beyond the operational impact of the CMO's departure. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Confirm the effective date of Dr. Lefebvre's departure (December 15, 2025).
- Verify the terms of the post-employment consulting arrangement.
- Monitor for subsequent announcements regarding the appointment of a permanent or interim Chief Medical Officer.